Aldeyra Therapeutics, Inc. (ALDX) stock
ALDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.69+0.02 (+3.63%)
Close on Nov 17, 2026Market cap $41.86MP/E –Yield –
Aldeyra Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Aldeyra Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$22.02M. For fiscal 2025 it was -$33.35M. The highest annual figure on record is -$1.71M in fiscal 2013.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$33.35M | – |
| FY2024 | Dec 31, 2024 | -$43.21M | – |
| FY2023 | Dec 31, 2023 | -$30.33M | – |
| FY2022 | Dec 31, 2022 | -$56.64M | – |
| FY2021 | Dec 31, 2021 | -$42.56M | – |
| FY2020 | Dec 31, 2020 | -$37.49M | – |
| FY2019 | Dec 31, 2019 | -$44.98M | – |
| FY2018 | Dec 31, 2018 | -$29.86M | – |
| FY2017 | Dec 31, 2017 | -$19.22M | – |
| FY2016 | Dec 31, 2016 | -$15.15M | – |
| FY2015 | Dec 31, 2015 | -$9.31M | – |
| FY2014 | Dec 31, 2014 | -$4.78M | – |
| FY2013 | Dec 31, 2013 | -$1.71M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$4.59M | – |
| Q1 FY2026 | Mar 31, 2026 | -$5.11M | – |
| Q4 FY2025 | Dec 31, 2025 | -$5.30M | – |
| Q3 FY2025 | Sep 30, 2025 | -$7.02M | – |
| Q2 FY2025 | Jun 30, 2025 | -$8.56M | – |
| Q1 FY2025 | Mar 31, 2025 | -$12.47M | – |
| Q4 FY2024 | Dec 31, 2024 | -$12.04M | -2505.3% |
| Q3 FY2024 | Sep 30, 2024 | -$7.97M | – |
| Q2 FY2024 | Jun 30, 2024 | -$13.22M | – |
| Q1 FY2024 | Mar 31, 2024 | -$9.97M | – |
| Q4 FY2023 | Dec 31, 2023 | $500.44K | – |
| Q3 FY2023 | Sep 30, 2023 | -$8.02M | – |
| Q2 FY2023 | Jun 30, 2023 | -$13.36M | – |
| Q1 FY2023 | Mar 31, 2023 | -$9.44M | – |
| Q4 FY2022 | Dec 31, 2022 | -$11.23M | – |
| Q3 FY2022 | Sep 30, 2022 | -$12.57M | – |
| Q2 FY2022 | Jun 30, 2022 | -$19.96M | – |
| Q1 FY2022 | Mar 31, 2022 | -$12.87M | – |
| Q4 FY2021 | Dec 31, 2021 | -$11.58M | – |
| Q3 FY2021 | Sep 30, 2021 | -$8.43M | – |
| Q2 FY2021 | Jun 30, 2021 | -$9.07M | – |
| Q1 FY2021 | Mar 31, 2021 | -$13.47M | – |
| Q4 FY2020 | Dec 31, 2020 | -$8.32M | – |
| Q3 FY2020 | Sep 30, 2020 | -$6.24M | – |
| Q2 FY2020 | Jun 30, 2020 | -$7.58M | – |
| Q1 FY2020 | Mar 31, 2020 | -$15.36M | – |
| Q4 FY2019 | Dec 31, 2019 | -$11.23M | – |
| Q3 FY2019 | Sep 30, 2019 | -$8.32M | – |
| Q2 FY2019 | Jun 30, 2019 | -$12.81M | – |
| Q1 FY2019 | Mar 31, 2019 | -$12.63M | – |
| Q4 FY2018 | Dec 31, 2018 | -$7.97M | – |
| Q3 FY2018 | Sep 30, 2018 | -$7.69M | – |
| Q4 FY2017 | Dec 31, 2017 | -$5.02M | – |
| Q3 FY2017 | Sep 30, 2017 | -$4.71M | – |
| Q2 FY2017 | Jun 30, 2017 | -$5.31M | – |
| Q1 FY2017 | Mar 31, 2017 | -$4.19M | – |
| Q4 FY2016 | Dec 31, 2016 | -$3.91M | – |
| Q3 FY2016 | Sep 30, 2016 | -$3.50M | – |
| Q2 FY2016 | Jun 30, 2016 | -$3.25M | – |
See a number that looks wrong?